ADSTILADRIN IS FULLY AVAILABLE.
ACCESS
Ferring Pharmaceuticals
Is Committed to
Helping Patients With Resources to Access Treatment
Reimbursement confidence with ADSTILADRIN1
99%
of claims paid to satisfaction
the first time
<25-day
average turnaround time
120 days
Flexible payment terms available*
ADSTILADRIN Average Sales Price (ASP) Leave Behind Download
A leave behind that outlines
the establishment of the ASP
for ADSTILADRIN
Patient and HCP Support Programs
Ferring stands behind the support services we offer. Access ADSTILADRIN support tools for your patients and clinic.
For your practice
Ferring Product Replacement Policy
Ferring will replace select Ferring products purchased directly from
Ferring or a Ferring-authorized
distributor without charge.
Replacement-eligible examples:
- In rare instances, if a patient is unable to retain the product per the minimal time reenacted in the
clinical trial - Product is prepared and unforeseen circumstances prevent administration
Ferring Product
Replacement Policy
Download
ADSTILADRIN Warranty Program
Ferring provides a warranty program in cases in which a patient is unable to retain the product in their
bladder for at least 15 minutes.
Warranty Program
Details
Download
Ferring Assurance
Ferring will reimburse the acquisition cost of ADSTILADRIN if:
- An office receives a positive coverage determination through Ferring Access Support
- The claim is not reimbursed by the payer after subsequent appeals
- Investigation verifies the inaccuracy/error made by Ferring Access Support
Ferring Assurance
Information
Download
For your patients
ADSTILADRIN Copay Program
Eligible, commercially insured patients may pay as little as $10 for each ADSTILADRIN prescription.
ADSTILADRIN Copay
Program
Leave Behind
Download
Ferring Access Support Patient Assistance
Program (PAP)
Qualified uninsured/underinsured patients enrolled in the Ferring Access Support Program may receive ADSTILADRIN at no cost.
- Income must be below 500% of the federal poverty level, adjusted for family size. Further restrictions apply
Ferring Access Support Patient Assistance
Program (PAP)
Download
Ferring Access Support is here for your patients and clinic
This strong, integrated hub service is designed to enhance the patient experience and drive reimbursement confidence and process within urology
Patient support services
- ADSTILADRIN Copay Program
- Ferring Access Support Patient Assistance Program (PAP)
- Referrals to third-party organizations including 501(c)(3) charitable organizations, patient support and education groups, and state health exchange resources
- Appointment scheduling assistance and adherence support
Benefits investigation support
- Determine patient coverage for ADSTILADRIN, procedure, and site of care
- Verify whether prior authorization/
precertification is required and what is needed for submission - Provide support and guidance on
applicable billing, coding, claims, and appeals
Fulfillment services
- Support and streamlining of the ADSTILADRIN ordering and delivery
process - Coordination of product shipment and patient instillation
Reimbursement confidence and support
- Dedicated team of specialists for all your coverage, access, and reimbursement
needs - Case Managers and Field Reimbursement Managers
- Flexible payment terms of up to 120 days
on buy-and-bill products1*
*Reserved for community practices, LUGPAs, Non-Hospital class trade only. Ferring offers approximately 120-day payment terms to its specialty distribution network. Payment terms offered from specialty distributor to HCP may
vary.
Sign Up to Receive Information and Updates on ADSTILADRIN (nadofaragene firadenovec-vncg)
Form ToggleReference: 1. Ferring Access Support services for you and your patients. Ferring Pharmaceuticals, Inc. 2025.
Important Safety Information
INDICATION
ADSTILADRIN is a non-replicating adenoviral vector-based gene therapy indicated for the treatment of adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors.
IMPORTANT SAFETY INFORMATION
CONTRAINDICATIONS: ADSTILADRIN is contraindicated in patients with prior hypersensitivity reactions to interferon alfa or to any component of the product.
WARNINGS AND PRECAUTIONS:
- Risk with delayed cystectomy: Delaying cystectomy in patients with BCG-unresponsive CIS could lead to development of muscle invasive or metastatic bladder cancer, which can be lethal. If patients with CIS do not have a complete response to treatment after 3 months or if CIS recurs, consider cystectomy.
- Risk of disseminated adenovirus infection: Persons who are immunocompromised or immunodeficient may be at risk for disseminated infection from ADSTILADRIN due to low levels of replication-competent adenovirus. Avoid ADSTILADRIN exposure to immunocompromised or immunodeficient individuals.
DOSAGE AND ADMINISTRATION: Administer ADSTILADRIN by intravesical instillation only. ADSTILADRIN is not for intravenous use, topical use, or oral administration.
USE IN SPECIFIC POPULATIONS: Advise females of reproductive potential to use effective contraception during ADSTILADRIN treatment and for 6 months after the last dose. Advise male patients with female partners of reproductive potential to use effective contraception during ADSTILADRIN treatment and for 3 months after the last dose.
ADVERSE REACTIONS: The most common (>10%) adverse reactions, including laboratory abnormalities (>15%), were glucose increased, instillation site discharge, triglycerides increased, fatigue, bladder spasm, micturition (urination urgency), creatinine increased, hematuria (blood in urine), phosphate decreased, chills, pyrexia (fever), and dysuria (painful urination).
You are encouraged to report negative side effects of prescription drugs to FDA. Visit www.FDA.gov/medwatch or call 1-800-332-10881-800-332-1088. You may also contact Ferring Pharmaceuticals at 1-888-FERRING1-888-FERRING.
Please see full Prescribing Information for ADSTILADRIN.